Shenyang Fuyang Pharmaceutical Technology Co., Ltd.

Shen Yang Tonglian Group Co., Ltd.

Shen Yang Fuyang Medicine Technology Co., Ltd.

Xiaofeng Zhao

Yang Jiang

Yiguang Wang

Mingyu Xia

Xunlei Jiang

Xundong Jiang

Enhong Jiang

Weiqing He

Jianlu Dai

Shengwu Yang

Weinqing He

Xulein Jiang

Yang Jang

A medicament for preventing and/or treating a disease is disclosed, the disease is Alzheimer's disease, diabetes or senility; and the medicament includes a first active ingredient, and the first active ingredient includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III.

Use of carrimycin or active ingredients thereof and use thereof

Use of carrimycin ininfection resistance comprises the main steps: measuring the activity of carrimycin inresistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separatedincluding drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercleinfected diseases are expected to be developed.

Use of carrimycin ininfection resistance

The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4&#x2033;-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Biosynthetic gene cluster of carrimycin

A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.

Genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I

Growing community of inventors

Liaoning, China

Xiaofeng Zhao